PL2040713T3 - Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR - Google Patents

Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR

Info

Publication number: PL2040713T3
Authority: PL; Poland
Prior art keywords: fxr; deseases; mediated; prevention; treatment
Prior art date: 2006-06-27

Application number

PL07809913T

Other languages

English (en)

Inventor

Roberto Pellicciari

Stefano Fiorucci

Mark Pruzanski

Original Assignee

Intercept Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-27

Filing date

2007-06-27

Publication date

2014-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2040713(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-27 Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc

2014-11-28 Publication of PL2040713T3 publication Critical patent/PL2040713T3/pl

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
239000003446 ligand Substances 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL07809913T 2006-06-27 2007-06-27 Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR PL2040713T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US81663506P	2006-06-27	2006-06-27
PCT/US2007/014829 WO2008002573A2 (en)	2006-06-27	2007-06-27	Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP07809913.2A EP2040713B1 (en)	2006-06-27	2007-06-27	Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions

Publications (1)

Publication Number	Publication Date
PL2040713T3 true PL2040713T3 (pl)	2014-11-28

Family

ID=38846269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07809913T PL2040713T3 (pl)	2006-06-27	2007-06-27	Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR

Country Status (14)

Country	Link
US (4)	US7932244B2 (pl)
EP (1)	EP2040713B1 (pl)
JP (1)	JP5222846B2 (pl)
CN (1)	CN101522703B (pl)
AU (1)	AU2007265457C1 (pl)
CA (1)	CA2656320C (pl)
CY (1)	CY1115533T1 (pl)
DK (1)	DK2040713T3 (pl)
ES (1)	ES2523591T3 (pl)
IL (2)	IL196169A (pl)
PL (1)	PL2040713T3 (pl)
PT (1)	PT2040713E (pl)
SI (1)	SI2040713T1 (pl)
WO (1)	WO2008002573A2 (pl)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE303399T1 (de)	2001-03-12	2005-09-15	Intercept Pharmaceuticals Inc	Steroide als agonisten für fxr
PL1734970T3 (pl)	2004-03-12	2015-05-29	Intercept Pharmaceuticals Inc	Leczenie zwłóknienia z zastosowaniem ligandów FXR
US10987362B2 (en)	2004-03-12	2021-04-27	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it)	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101522703B (zh)	2006-06-27	2013-04-17	英特塞普特医药品公司	胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
JP5292310B2 (ja)	2007-01-19	2013-09-18	インターセプトファーマシューティカルズ，インコーポレイテッド	Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA020310B1 (ru) *	2008-07-30	2014-10-30	Интерсепт Фармасьютикалз, Инк.	Модуляторы рецептора tgr5 и их применение
ES2663948T3 (es)	2008-11-19	2018-04-17	Intercept Pharmaceuticals, Inc.	Moduladores de TGR5 y método de uso de los mismos
JP2012509892A (ja)	2008-11-26	2012-04-26	サティオゲンファーマシューティカルズ，インク．	サティオゲン類を含有する組成物及び使用の方法
EP2367554A4 (en)	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid reflux inhibitor for the treatment of obesity and diabetes
US20110257139A1 (en)	2008-12-19	2011-10-20	Royal College Of Surgeons In Ireland	Treatment of diarrhoea
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140441A2 (en)	2010-05-06	2011-11-10	Children's Hospital Medical Center	Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3593802A3 (en) *	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ITRM20100329A1 (it) *	2010-06-15	2011-12-16	Franco Baldelli	Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2525223A1 (en) *	2011-05-19	2012-11-21	Universiteit Maastricht	In vitro method for predicting in vivo genotoxicity of chemical compounds.
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
US11154559B2 (en)	2011-09-29	2021-10-26	Ethicon Endo-Surgery, Inc.	Methods and compositions of bile acids
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
PT3336097T (pt)	2012-06-19	2020-10-29	Intercept Pharmaceuticals Inc	Preparação da forma não cristalina de ácido obeticólico
US9982008B2 (en)	2012-06-19	2018-05-29	Intercept Pharmaceuticals, Inc.	Preparation and uses of obeticholic acid
HUE036887T2 (hu) *	2012-10-26	2018-08-28	Intercept Pharmaceuticals Inc	Eljárás epesav-származékok elõállítására
SG11201503697TA (en)	2012-11-28	2015-06-29	Intercept Pharmaceuticals Inc	Treatment of pulmonary disease
CA2912139C (en) *	2013-05-14	2021-04-20	Roberto Pellicciari	11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP3027637B1 (en) *	2013-08-01	2019-10-09	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	The glycine conjugate of beta-muricholic acid as an inhibitor of the farnesoid x receptor for the treatment of obesity, insulin resistance or non-alcoholic fatty liver disease
PL3043865T3 (pl) *	2013-09-11	2021-07-05	Institut National De La Santé Et De La Recherche Médicale (Inserm)	SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
MX356006B (es) *	2013-10-18	2018-04-24	Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C	Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
CA3236835A1 (en)	2013-11-22	2015-05-28	Mina Therapeutics Limited	C/ebp alpha short activating rna compositions and methods of use
EP3712254A1 (en)	2014-05-28	2020-09-23	Children's Hospital Medical Center	Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3626725B1 (en)	2014-05-29	2022-11-30	Bar Pharmaceuticals S.r.l.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
SG11201701723XA (en)	2014-09-24	2017-04-27	Gilead Sciences Inc	Methods of treating liver disease
WO2016045480A1 (zh) *	2014-09-28	2016-03-31	上海源力生物技术有限公司	一种奥贝胆酸的制备方法
CA2963704A1 (en)	2014-10-17	2016-04-21	Children's Hospital Medical Center	In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
HK1243930A1 (zh)	2014-11-06	2018-07-27	英安塔制药有限公司	作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
EP3221331B1 (en)	2014-11-19	2019-09-18	Nzp Uk Limited	6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
JP6698085B2 (ja)	2014-11-19	2020-05-27	エヌゼットピーユーケーリミテッド	ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
EP3221333B1 (en)	2014-11-19	2019-07-24	NZP UK Limited	6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
EA033445B1 (ru)	2014-11-19	2019-10-31	Nzp Uk Ltd	5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
HK1244708A1 (zh)	2014-11-26	2018-08-17	英安塔制药有限公司	作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) *	2014-11-26	2016-06-02	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
TN2017000344A1 (en) *	2015-02-06	2019-01-16	Intercept Pharmaceuticals Inc	Pharmaceutical compositions for combination therapy
MX2017010376A (es)	2015-02-11	2017-12-20	Enanta Pharm Inc	Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
WO2016161003A1 (en)	2015-03-31	2016-10-06	Enanta Phamraceuticals, Inc.	Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en)	2015-04-07	2021-01-19	Intercept Pharmaceuticals, Inc.	FXR agonist compositions for combination therapy
WO2016173493A1 (en) *	2015-04-28	2016-11-03	Shanghai De Novo Pharmatech Co. Ltd.	Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
EP3124080A1 (en)	2015-07-28	2017-02-01	Merz Pharma GmbH & Co. KGaA	Semisynthetic bile acids for injection lipolysis
WO2017053428A1 (en)	2015-09-21	2017-03-30	Intercept Pharmaceuticals, Inc.	Methods of promoting hepatic regeneration
CN108350020A (zh) *	2015-09-24	2018-07-31	英特塞普特医药品公司	用于制备胆汁酸衍生物的方法和中间体
KR20180061351A (ko) *	2015-10-07	2018-06-07	인터셉트 파마슈티컬즈, 인크.	파네소이드 x 수용체 조절제
IL243707A0 (en)	2016-01-20	2016-05-01	Galmed Res And Dev Ltd	Treatment to regulate the microbiota in the intestine
WO2017142895A1 (en) *	2016-02-15	2017-08-24	Regents Of The University Of Minnesota	Compositions and methods for treating clostridium associated diseases
US20170233431A1 (en) *	2016-02-17	2017-08-17	City Of Hope	Bile acid derivatives and methods for synthesis and use
US10323061B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
TW201733582A (zh)	2016-03-28	2017-10-01	大日本住友製藥股份有限公司	Fxr促效劑及arb之組合醫藥
WO2017180577A1 (en) *	2016-04-13	2017-10-19	Intercept Pharmaceuticals, Inc.	Methods of treating cancer
EP4177335A1 (en)	2016-05-05	2023-05-10	Children's Hospital Medical Center	Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201608776D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Methods and compounds
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
CA3252823A1 (en)	2016-06-13	2025-02-25	Gilead Sciences, Inc.	Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
BR112018075734A2 (pt)	2016-06-13	2019-04-02	Gilead Sciences, Inc.	composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3038534A1 (en) *	2016-09-30	2018-04-05	Intercept Pharmaceuticals, Inc.	Crystalline forms of a bile acid derivative
SG11201903697WA (en)	2016-11-04	2019-05-30	Childrens Hospital Med Ct	Liver organoid compositions and methods of making and using same
US11197870B2 (en)	2016-11-10	2021-12-14	Galmed Research And Development Ltd	Treatment for hepatic fibrosis
CN110121347A (zh)	2016-11-29	2019-08-13	英安塔制药有限公司	制备磺酰脲胆汁酸衍生物的方法
EP3548507A4 (en)	2016-12-05	2020-07-15	Children's Hospital Medical Center	COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
US10472386B2 (en)	2017-02-14	2019-11-12	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR agonists and methods of use thereof
TW201832768A (zh) *	2017-03-07	2018-09-16	英特賽普醫藥品公司	治療癌症的方法
US20180256600A1 (en) *	2017-03-07	2018-09-13	Intercept Pharmaceuticals, Inc.	Methods of treating cancer
CN110461328A (zh)	2017-03-28	2019-11-15	吉利德科学公司	治疗肝疾病的治疗组合
US20210085662A1 (en)	2017-03-30	2021-03-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
BR112019020780A2 (pt)	2017-04-07	2020-04-28	Enanta Pharm Inc	processo para preparação de derivados de ácido biliar de carbamato de sulfonila
EP3609997A4 (en)	2017-04-14	2021-03-03	Children's Hospital Medical Center	COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
MX2020000873A (es)	2017-07-24	2020-07-22	Intercept Pharmaceuticals Inc	Derivados de ácidos biliares marcados isotópicamente.
CA3075205A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	Stabilized hnf4a sarna compositions and methods of use
US12297457B2 (en)	2017-10-10	2025-05-13	Children's Hospital Medical Center	Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en)	2017-12-21	2021-09-08	Children's Hospital Medical Center	DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US12421500B2 (en)	2018-07-26	2025-09-23	Children's Hospital Medical Center	Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
US11208571B2 (en)	2018-08-08	2021-12-28	University Of Maryland, College Park	Methods for nondestructive dispersing of carbon nanomaterials in water
JP2021535753A (ja)	2018-09-12	2021-12-23	チルドレンズホスピタルメディカルセンター	造血幹細胞およびその派生体の生成のためのオルガノイド組成物
EP4360632B1 (en)	2019-01-15	2025-10-29	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
WO2020160371A1 (en)	2019-02-01	2020-08-06	The University Of Hong Kong	Innervated organoid compositions and methods of making same
US20220096495A1 (en) *	2019-02-04	2022-03-31	Intercept Pharmaceuticals, Inc.	Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
US11524005B2 (en)	2019-02-19	2022-12-13	Gilead Sciences, Inc.	Solid forms of FXR agonists
EA202193334A1 (ru)	2019-05-30	2022-03-14	Интерсепт Фармасьютикалз, Инк.	Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
CN114174494A (zh)	2019-05-31	2022-03-11	儿童医院医学中心	产生和扩增造血干细胞的方法
CA3141814A1 (en)	2019-05-31	2020-12-03	Children's Hospital Medical Center	Shaped organoid compositions and methods of making same
CN112142814B (zh) *	2019-06-26	2021-09-28	江苏吉贝尔药业股份有限公司	牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
AU2020312735A1 (en)	2019-07-18	2021-12-16	Enyo Pharma	Method for decreasing adverse-effects of interferon
US20230060715A1 (en)	2020-01-15	2023-03-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fxr agonists for treating an infection by hepatitis d virus
US20240100125A1 (en)	2021-01-14	2024-03-28	Enyo Pharma	Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN117320722A (zh)	2021-04-28	2023-12-29	埃尼奥制药公司	使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN119950519B (zh) *	2025-01-07	2025-11-21	山东省海洋科学研究院(青岛国家海洋科学研究中心)	奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5014206A (en)	1988-08-22	1991-05-07	Facilitech International Incorporated	Tracking system
DE9011787U1 (de)	1990-08-14	1990-10-25	Fritz Schäfer GmbH, 5908 Neunkirchen	Identifikationseinheit für Müllbehälter
US5121853A (en)	1991-07-30	1992-06-16	Waste Management Of North America	Garbage container
DE9204254U1 (de)	1992-03-28	1992-06-17	Fritz Schäfer GmbH, 5908 Neunkirchen	Müllbehälter, insbesondere Müllgroßraumbehälter, mit einer Identifikationseinheit
ZA947912B (en)	1993-10-12	1995-05-24	Broadbent J W Nominees Pty Ltd	Treatment of medical disorders associated with free radical formation
US5541348A (en)	1994-03-10	1996-07-30	National Research Council Of Canada	Bile acids for biological and chemical applications and processes for the production thereof
US5565846A (en)	1994-04-25	1996-10-15	Indala Corporation	Reader system for waste bin pickup vehicles
FR2784364B1 (fr)	1998-10-13	2000-12-15	Plastic Omnium Cie	Bac pour la collecte de dechets, equipe d'un transpondeur
ES2326850T3 (es)	1998-12-23	2009-10-20	Glaxo Group Limited	Ensayos para ligandos de receptores nucleares.
US6448898B1 (en)	1999-12-16	2002-09-10	Cardinal Automation, Inc.	System for auditing refuse collection
DE10030905C2 (de)	2000-06-24	2003-08-07	Der Gruene Punkt Duales Syst	Verwendung von Transpondern bei der Dokumentation und Handhabung von Abfällen
ATE303399T1 (de) *	2001-03-12	2005-09-15	Intercept Pharmaceuticals Inc	Steroide als agonisten für fxr
US7078396B2 (en) *	2001-05-03	2006-07-18	Arch Development Corporation	Method of treating disorder related to high cholesterol concentration
JP5384777B2 (ja)	2001-12-18	2014-01-08	有限会社大長企画	強筋肉剤、抗炎症剤
US6975229B2 (en)	2002-08-09	2005-12-13	Battelle Memorial Institute K1-53	System and method for acquisition management of subject position information
US20040229453A1 (en) *	2003-05-15	2004-11-18	Jsr Micro, Inc.	Methods of pore sealing and metal encapsulation in porous low k interconnect
EP1568706A1 (en)	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
CN101522703B (zh)	2006-06-27	2013-04-17	英特塞普特医药品公司	胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用

2007
- 2007-06-27 CN CN2007800321119A patent/CN101522703B/zh not_active Expired - Fee Related
- 2007-06-27 AU AU2007265457A patent/AU2007265457C1/en not_active Ceased
- 2007-06-27 EP EP07809913.2A patent/EP2040713B1/en active Active
- 2007-06-27 PL PL07809913T patent/PL2040713T3/pl unknown
- 2007-06-27 JP JP2009518230A patent/JP5222846B2/ja not_active Expired - Fee Related
- 2007-06-27 US US11/819,517 patent/US7932244B2/en active Active
- 2007-06-27 CA CA2656320A patent/CA2656320C/en active Active
- 2007-06-27 DK DK07809913.2T patent/DK2040713T3/da active
- 2007-06-27 PT PT78099132T patent/PT2040713E/pt unknown
- 2007-06-27 ES ES07809913.2T patent/ES2523591T3/es active Active
- 2007-06-27 WO PCT/US2007/014829 patent/WO2008002573A2/en not_active Ceased
- 2007-06-27 SI SI200731515T patent/SI2040713T1/sl unknown
2008
- 2008-12-25 IL IL196169A patent/IL196169A/en active IP Right Grant
2011
- 2011-04-07 US US13/082,261 patent/US8546365B2/en active Active
2012
- 2012-09-03 IL IL221764A patent/IL221764A/en active IP Right Grant
2013
- 2013-08-28 US US14/012,401 patent/US9090652B2/en not_active Expired - Fee Related
2014
- 2014-09-16 CY CY20141100746T patent/CY1115533T1/el unknown
2015
- 2015-06-18 US US14/743,295 patent/US9763964B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2656320C (en)	2015-04-28
US20120283234A1 (en)	2012-11-08
AU2007265457A1 (en)	2008-01-03
WO2008002573A2 (en)	2008-01-03
SI2040713T1 (sl)	2014-11-28
EP2040713B1 (en)	2014-06-18
US7932244B2 (en)	2011-04-26
EP2040713A4 (en)	2012-08-29
CA2656320A1 (en)	2008-01-03
US20140057886A1 (en)	2014-02-27
EP2040713A2 (en)	2009-04-01
US9090652B2 (en)	2015-07-28
CN101522703B (zh)	2013-04-17
AU2007265457B2 (en)	2012-06-14
US8546365B2 (en)	2013-10-01
US20150359805A1 (en)	2015-12-17
CN101522703A (zh)	2009-09-02
ES2523591T3 (es)	2014-11-27
CY1115533T1 (el)	2017-01-04
HK1130187A1 (en)	2009-12-24
IL196169A0 (en)	2009-09-22
AU2007265457C1 (en)	2012-11-29
IL221764A (en)	2016-09-29
US20080182832A1 (en)	2008-07-31
PT2040713E (pt)	2014-10-13
DK2040713T3 (da)	2014-09-29
IL221764A0 (en)	2012-10-31
US9763964B2 (en)	2017-09-19
WO2008002573A3 (en)	2008-02-28
JP5222846B2 (ja)	2013-06-26
JP2010500285A (ja)	2010-01-07
IL196169A (en)	2012-10-31

Publication	Publication Date	Title
SI2040713T1 (sl)	2014-11-28	Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
PL2118074T3 (pl)	2014-06-30	Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
HUS1800006I1 (hu)	2018-05-02	Alfa-MSH származékok fotodermatózisok kezelésére
PT1987141T (pt)	2019-03-04	Composições adequadas ao tratamento de doenças mediadas pelo colagénio
IL198847A (en)	2015-07-30	Process for making 2-imino-thiazolidine-4-on and several such histories
IL187565A0 (en)	2008-03-20	Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2007101161A8 (en)	2007-12-27	Methods and compositions for the treatment of gastrointestinal disorders
ZA201001264B (en)	2011-07-27	1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
PL2254589T3 (pl)	2017-11-30	Związki i sposoby zapobiegania lub leczenia restenozy
ZA200904573B (en)	2010-09-29	Compositions comprising bile acid sequestrants for treating esophageal disorders
GB0909297D0 (en)	2009-07-15	Composition for the treatment of skin conditions
PL2234631T3 (pl)	2013-03-29	Związki i metody stosowane w terapii choroby naczyniowej
IL192933A0 (en)	2009-02-11	Benzoisoindole derivatives for the treatment of pain
GB0808730D0 (en)	2008-06-18	Compositions and methods for the prevention and treatment of schistosomiasis
GB0618309D0 (en)	2006-10-25	Compositions and methods for the treatment of disease
GB0617280D0 (en)	2006-10-11	Compositions and methods for the treatment of neurological damage
ZA200806180B (en)	2009-07-29	Benzoisoindole derivatives for the treatment of pain
IL197485A0 (en)	2009-12-24	Use of vitamin d compounds for the prevention of adhesions
GB0601091D0 (en)	2006-03-01	The Treatment Of Ocular Conditions
AU2008903693A0 (en)	2008-08-07	Compositions and methods for the prevention and treatment of cancer
AU2008905198A0 (en)	2008-10-23	Compositions and Methods for the Prevention and Treatment of Cancer
ZA200805398B (en)	2009-12-30	Use of kcnq-openers for treating or reducing the symptons of schizophrenia
IL194261A0 (en)	2009-09-22	S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
HK1122032A (en)	2009-05-08	Benzoisoindole derivatives for the treatment of pain
ZA200605368B (en)	2008-11-26	Gallic acid derivative and process of preparing the same